Kalaris Therapeutics, Inc. — Income Charts
1 years of history · ending 2019-12-31 · SEC EDGAR
Source:10-K · 10-Q
Revenue, Gross Profit, Operating Income & Net Income
Margin (%)
Operating Expenses
Income Breakdown
Revenue
$165K
R&D
$16M
D&A
$19K
Operating Income
$-27M
EBITDA
$-27M
Interest Expense
—
Interest Income
$2M
Other Income/Expense
$797K
Pretax Income
$-24M
Tax Provision
—
Net Income
$-24M
Operating Margin
-16182.4%
Net Margin
-14447.9%
Effective Tax Rate
—
Deferred Tax Assets
$4M
DTA Valuation Allowance
$7M
Tax Credit Carryforwards
$753K
NOL Carryforwards
$8M
ETR (Continuing Operations)
—
ETR Federal Statutory
21.0%
ETR State + Local (pp)
2.4%
ETR Foreign Differential (pp)
—
Operating Lease Cost
$2M
Income YoY Variation
—